1337 results about "Liver injury" patented technology

The present invention relates to formulations and methods for preventing and treating liver injury and fibrosis in cholestasis. This is accomplished by the administration of a composition which includes selected antioxidants.

The present disclosure provides an extended release pharmaceutical composition comprising hydrocodone and acetaminophen that provides a rapid onset of analgesia, and reduced levels of acetaminophen near the end of the dosing interval. Also provided are methods for reducing the risk of acetaminophen-induced hepatic damage in a subject being treated with an acetaminophen containing composition, as well as methods for treating pain in a subject in need thereof.

The invention provides a Tibetan virgate wormwood herb extract containing swertiamain, gentiopicroside, sweroside, mangiferin and isoorientin, and the weight ratio of the five ingredients is (0.04-0.71): (20-40): (1-15): (1.6-26): (0.01-0.16). The invention further provides a preparation method of the Tibetan virgate wormwood herb extract, a pharmaceutical composition containing the Tibetan virgate wormwood herb extract and a medical use of the Tibetan virgate wormwood herb extract. The Tibetan virgate wormwood herb extract can improve various indicators caused by liver injury, promote the reversal of the liver fibrosis process and better prevent liver cirrhosis.

A process for extracting danshinolic acids A and B from red sage root includes soaking in hot water, collecting liquid extract, centrifugal separating, ultrafiltering of supernatant, extracting by reverse-phase column or acetate, acidifying, separating organic phase to recover solvent, and separating by reverse-phase column. A freeze dried injection for preventing and treating liver injury and hepafibrosis is prepared from said danshinolic acids A and B and additives. Its advantages are high purity and high output rate.

An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition comprises a multiparticulate modified release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules as the primary package. The oral dosage units are supplied as part of a kit, which also includes a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment.

The invention relates to a preparation method of a xylitol liver-protecting tablet, belonging to the technical field of medical health care. The formula of the xylitol liver-protecting tablet comprises the following raw materials in proportion: 15-45 parts of kudzu root extract, 2-20 parts of glycyrrhizic acid, 5-35 parts of propolis powder, 20-60 parts of xylitol, 1-10 parts of low-substituted hydroxypropyl cellulose, 1-10 parts of cross-linked sodium carboxymethyl cellulose and 0.5-5 parts of magnesium stearate; and a coating agent comprises 0.5-40 parts of hydroxypropyl methylcellulose, 1-30 parts of polyethylene glycol 6000, 0.5-40 parts of talcum powder, 0.5-30 parts of titanium pigment, 0.5-30 parts of iron oxide brown and 10-75 parts of maltitol. The finished product of the xylitol liver-protecting tablet is prepared by the processing steps of crushing, mixing, tabletting, coating and the like. In the invention, by using the xylitol as a main raw material and adding partial auxiliary materials, the xylitol liver-protecting tablet which is a health food and has auxiliary protection effect on chemical liver injury is prepared. The xylitol liver-protecting tablet can effectively prevent and treat fatty liver; and after patients suffering from the fatty liver take the xylitol liver-protecting tablet, severe fatty liver can be relieved into moderate fatty liver, and moderate fatty liver can be relieved into mild fatty liver. Thus, the xylitol liver-protecting tablet has obvious benefit to improve liver functions of human bodies and has wide market prospects.

The present invention presents compounds that inhibit phosphodiesterase 4 having Formula (I). The present invention also provides methods of using the compounds of Formula (I) to prevent or treat asthma, atopic dermatitis, rheumatoid arthritis, inflammatory bowel disorders, pulmonary hypertension, liver injury, bone loss, septic shock, or multiple sclerosis, and to pharmaceutical compositions that contain the compounds of Formula (I).

Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.

The invention discloses a compound that can overall replenish nutriments required by human body and use thereof. The compound consists of polyunsaturated fatty acid, an anti-oxidant, soyabean lecithin, probiotic, ganoderma and trace nutriments. The nutriment compound of the invention has the functions of accelerating the growth of human, regulating immunity, preventing and treating knub, high blood fat, liver injury, astriction, etc. Compared with similar products, the invention is characterized by a complete formula, reasonable mixture ratio of each constituent and synergic effects between the constituents, and so on, thereby being favorable for keeping the normal metabolism of human body and preventing and curing varied diseases, and having the effect of prolonging life with long-term intake.

The invention relates to compound probiotics and a preparation method thereof. The compound probiotics comprise ten or more probiotics and two or more prebiotics. The invention also provides the preparation method of the compound probiotics. The preparation method comprises the following steps: firstly, mixing the compound probiotics according to the proportion, passing through a sieve with 80 to 120 meshes, then taking siftage and weighing; secondly, mixing the weighed materials; thirdly, tabletting mixed materials. According to the compound probiotics and the preparation method thereof disclosed by the invention, by scientifically mixing the probiotics with the prebiotics, the efficacy of the compound probiotics is effectively improved, living cell concentration is high, and the efficacy realizing time of the probiotics is shortened; compared with other products in the market, the compound probiotics have the advantages that acid and bile salt resisting capabilities are good; if the compound probiotics are administrated for one month, the improvement rate of constipation reaches 100 percent, the improvement rate of chronic colitis reaches 100 percent, the positive-to-negative rate of helicobacter pylori reaches 82 percent, the rehabilitation rate of chemical liver injury reaches 88 percent, the rehabilitation rate of anaphylactic rhinitis is 91 percent, the rehabilitation rate of female vaginitis reaches 93 percent, the improvement rate of phlegm-dampness constitution reaches 100 percent, the improvement rate of damp-heat constitution reaches 100 percent, and the improvement rate of acnes reaches 98 percent.

The invention provides a preparation method and application of physiologically active notoginseng polysaccharide. The method comprises the steps of refining and purifying by applying resin column chromatography, activated carbon and membrane separation and purification technology, and the like, so as to obtain the notoginseng polysaccharide. The notoginseng polysaccharide obtained by the preparation method provided by the invention has the characteristics of low protein, heavy metal and ash contents and stable quality, has the physiological activities of immunity regulation, liver injury protection, blood glucose decrease, tumor resisting and the like, and can be used singly or combined as raw materials for natural medicines and health products. The preparation method of the notoginseng polysaccharide, provided by the invention, is simple to operate, applicable for industrial production and low in cost and reaches the purposes of energy saving and consumption reduction and realizing comprehensive development and sustainable utilization of the rare Chinese traditional medicine, namely, notoginseng.

The invention discloses a new method for screening an anti-liver injury medicament by using a model organism zebra fish. The method comprises the following steps: continuously molding the zebra fish serving as a molding object for 3 days by using preferred carbon tetrachloride at the concentration of 1mmol/L to obtain the zebra fish of a liver injury model, and then evaluating the anti-liver injury activity of different receptor medicaments by using ALT and AST levels in the liver tissue of the zebra fish and the pathological change condition of the liver tissue of the zebra fish. Experimental results show that the new method for screening the anti-liver injury medicament by using the model organism zebra fish has high molding success rate, can simulate an in vivo environment to perform quick screening, and has the advantages of strong operability, accurate experimental results, little amount of required reacceptance medicament, strong repeatability, low cost, wide application range, capability of performing batch screening experiments and high work efficiency.

This invention relates to natual medicine chemical and medical technique field. It discloses two kind celosin new compounds of celosin A and celosin B structure and its distillation and eperating method from amaranthcea plant celosin. Their chemical general formula is shown as formula (1). This invention also discloses the compound and its derivative medicine aspect application of curing and preventing fatty liver, liver injury, hepatic fibrosis, liver cirrhosis, coronary heart disease, cardiac infarction, myocardial ischemia, cerebral ischemia, cerebral infarction, cerebral apoplexy, diabetes mellitus, hyperinsulinism, insulin resistance disease, obesity, glucose intolerance capability, and/or hypertension adiposity, hyperlipemia, dementia, depression or anxiety, and insomnia diseases.

The invention discloses a preparation method of weight-reducing lipid-lowering probiotics fermented soya-bean milk, which comprises the following steps: selecting soybeans, cleaning and soaking the soybeans, pulping to obtain soya-bean pulp, and preparing soya-bean milk; inoculating bifidobacterium bifidum, lactobacillus casei, and lactobacillus plantarum according to a ratio of bifidobacterium bifidum:lactobacillus casei:lactobacillus plantarum=4:3:3 to obtain a working fermentation agent for the probiotics fermented soya-bean milk; fermenting the soya-bean milk at a constant temperature of 37-45 DEG C for 2-6 hours; performing post-fermentation of the fermented soya-bean milk at 4 DEG C for 12 hours; packaging and refrigerating the product to finish the preparation of the probiotics fermented soya-bean milk. According to the invention, probiotics is adopted to ferment the soya-bean milk, and the prepared soya-bean milk is applicable to prevention and alleviation of non-alcoholic liver injury, has no other toxic or side effects, and causes no secondary injury to the liver. In addition, the preparation method of the invention is low in cost, has good development prospects, and well solves the current problem of lack of food and health-care products for preventing and alleviating non-alcoholic liver injury.

The invention discloses an artemisia sacrorum extract which contains total-flavone compounds, wherein the total-flavone compounds comprise one or more of 6-methoxy-quercetagetin-7-O-beta-D-glucoside, quercetin-3-O-beta-D-glucoside, isorhamnetin, queretagetin-3-O-beta-D-glucoside, acacetin-7-O-beta-D-glucoside, rutin, 5,7,4'-trihydroxyflavone, 3,3',4',5,7-pentahydroxyflavone, 5,7,4'-trihydroxy-3'-methoxyflavone, kaempferol, 3,5,7,4'-tetrahydroxy-6-methoxyflavone, 3',4',5,7-tetrahydroxyflavone, 5,7,4'-trihydroxy-6,3'-dimethoxyflavone, 5,7,4'-trihydroxy-6-methoxyflavone, quercitrin, 7,3',4'-trimethyl quercetin, 5-hydroxy-7,4'-dimethoxyflavone, 5,4'-dihydroxy-7-methoxyflavone genkwanin, 5,7-dihydroxy-4'-methoxyflavone, 5,7,3'-dihydroxy-4-methoxyflavone and derivatives. The artemisia sacrorum extract has remarkable prevention and treatment effects on liver injury.

The invention discloses a liver injury and repair type active peptide prepared from tuna offal. The active peptide is shown as an amino acid sequence of Met-Thr-His-Asp-Asp-Val-Asp-Glu. The active peptide has the advantages that the collagen peptide with the liver injury and repair functions is extracted from an aquatic product processing byproduct, namely tuna offal simply and easily at a low production cost, so that the aquatic product processing byproduct value can be increased remarkably, waste is avoided and environment protection is achieved, and preliminary basis can be provided for related functional food.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

The invention relates to a food, in particular to honey tea which has an assistant protective function to chemical liver injury. The effective components of the honey tea are made of materials in part by weight as follows: 40-50 parts of tea, 40-50 parts of Aloe vera fresh leaves, 40-50 parts of fresh folium mori, 40-50 parts of blueberry, 10 parts of agar, 40-50 parts of fructus ligustri lucidi, 10 parts of rice bran and 600-800 parts of honey. The materials are abundant in nutrition, healthy, safe and free from any side effects without damaging nutritional components of honey and medicinal materials. The preparation method comprises the steps of: drying and frying materials in a certain weight ratio such as tea, Aloe vera fresh leaves, fresh folium mori, blueberry, agar, fructus ligustri lucidi and rice bran with slow fire; pouring the materials into a stainless steel sealed tank which contains honey in a certain weight ratio; and stirring and fermenting for 25 days under constant temperature sealing condition to prepare the honey tea. The honey tea is simple in process, beneficial to absorption and lasting in assistant pesticide effect, and saves the use level.

A cyclodextrin derivative for preventing and treating cardiovascular and cerebrovascular diseases, diabetes, liver injury, diseases in respiratory system, rheumatic and rheumatoid diseases, dermatopathy and tumor is disclosed. It is an artificial analogue enzyme with the activity of glutathion peroxidase.

The invention discloses a ginseng drink and its production technology. Every 1000ml of the ginseng drink contains: 10g of ginseng, 10g of honeysuckle, 10g of mulberries, 10g of Chinese wolfberries, 0.1g of sucralose, 1g of potassium sorbate, and the balance drinking water. The ginseng drink is prepared by the technological steps of: material selection, material washing, slicing, drying, ginseng extract extraction and concentration, extraction and concentration of honeysuckle, mulberry and Chinese wolfberry extract, and ginseng drink preparation. Taking the ginseng drink provided in the invention can strengthen human constitution and improve disease resistance. The ginseng drink of the invention has the effects of clearing away heat and toxic materials, enriching blood and nourishing yin, promoting the secretion of saliva or body fluid and moistening dryness, and can also enhance nonspecifc immunity, delay ageing, resist liver injury, lower blood sugar, reduce blood pressure, tonify the kidney, protect the liver, resist fatigue and tumors.

The invention discloses a composition with an auxiliary protection effect on an alcoholic liver injury and a preparation method of the composition. The composition with the auxiliary protective effect on the alcoholic liver injury is mainly prepared from the following raw materials in parts by weight: 57.5-172.5 parts of kudzuvine root extract, 22.5-67.5 parts of semen hoveniae extract, 35-105 parts of salvia miltiorrhiza extract, 18-57 parts of turmeric extract and 7.5-22.5 parts of ammonium glycyrrhetate. The raw materials respectively have anti-lipid peroxidation effect and protective effect on the liver. Functional tests show that the composition with the auxiliary protection effect on the alcoholic liver injury has better liver protection effect compared with the same dose of single kudzuvine root extract preparation and single semen hoveniae extract preparation, and liver fatty degeneration and liver lipid peroxidation which are caused by the alcoholic liver injury can be obviously alleviated. The composition with the auxiliary protection effect is prepared by adopting a scientific and reasonable production process, is definite in functions, controllable in quality and safe to take and is applicable to a large group of people suffering from the alcoholic liver injury.

The invention relates to human sDR5-Fc recombinant fusion protein and application of the human sDR5-Fc recombinant fusion protein to preparation of medicine for preventing and treating drug induced liver injury. Through long-time study of the inventor, the protein gene sequence is selected again, and the novel human sDR5-Fc recombinant fusion protein provided by the invention is obtained. Through a great number of experiments, the human sDR5-Fc recombinant fusion protein can obviously reduce the serum transaminase level in various mouse drug induced liver injury models; the liver pathologic damage is reduced; the liver cell apoptosis rate is obviously reduced; the mouse survival ratio is improved. The human sDR5-Fc recombinant fusion protein is used as novel candidate medicine for preventing and treating the drug induced liver injury; the treatment range is wide; targets are specific; the action is special and fast; the curative effect is obvious; the safety is high; great development potential is realized.

The present invention provides methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of disease and/or toxicity, disease staging, target identification/validation, and monitoring of drug efficacy/toxicity. The present invention further provides suites of small molecule entities as biomarkers for non-invasive and early prediction of hepatic injury.

The invention relates to a starch composite hemostatic dressing of mesoporous silica microspheres, which adopts a sol-gel method and uses a three-block copolymer pluronic as a template agent to synthesize mesoporous silica microspheres with a pore diameter of about 5 nm. It is compounded with starch to prepare a mesoporous silicon oxide microsphere/starch composite hemostatic dressing, and the hemostatic performance of the composite material is observed through animal experiments. The mesoporous silica microsphere/starch composite material not only has strong water absorption performance, but also has obvious in vitro coagulation performance, which can significantly shorten the partial thromboplastin time and prothrombin time. The mesoporous silica microsphere/starch composite material can prevent the bleeding of the rabbit's back skin and liver injury and shorten the bleeding time, and has obvious hemostatic effect.

The invention discloses a method for establishing a seroglycoid N-glycome atlas model of chronic hepatitis liver injury. The method comprises the following steps: detecting a seroglycoid N-glycome atlas by using a G-Test detection method, establishing an N-glycome atlas model with significant difference between liver injury patients and normal control personnel, and screening NG1A2F with significant expression difference between a liver injury group and a normal control group. Based on the N-glycome atlas model established by the method disclosed by the invention, the detection sensitivity andspecificity of liver injury respectively reach 80.0% and 74.4%. In subsequent applications, the degree of liver injury of personnel to be detected can be detected by comparing the peak values of single peak NG1A2F in the N-glycome atlas of the serum of the personnel to be detected and in the atlas model established by the method. Based on the method disclosed by the invention, a plurality of patients with chronic hepatitis liver injury can be subjected to routine and non-invasive detection to help doctors and the patients to monitor the occurrence and progression of the chronic hepatitis liver injury in time, and the method is expected to be promoted and used in clinical practice.

The invention belongs to the field of food health protection, and particularly discloses a preparation method and application of turmeric fruit and vegetable enzyme. The preparation method comprises the following steps: (1) cleaning, airing and smashing fruits and vegetables to obtain a mixed fruit and vegetable solution; (2) adding sugar into the mixed fruit and vegetable solution, inoculating saccharomycetes, carrying out sealed fermentation, and when the pH is less than 4.3, obtaining primary fermented liquid; (3) inoculating compound lactobacillus into the primary fermented liquid for secondary fermentation, wherein the compound lactobacillus comprises lactobacillus plantarum, lactobacillus casei and bacillus aceticus; carrying out sealed fermentation, and when the pH is less than 3.8, adding a turmeric extract into the fruit and vegetable solution for continuous fermentation for 10 days to obtain secondary fermented liquid; (4) filtering or centrifuging the secondary fermented liquid, and homogenizing and sterilizing filtrate or centrifuged supernate to obtain the turmeric fruit and vegetable enzyme. The prepared turmeric fruit and vegetable enzyme has a liver protecting effect, and is suitable for long-term prevention and health care application of people working under a high chemical liver injury risk environment.